| Year |
Citation |
Score |
| 2024 |
Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keinänen OM, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer. Molecular Pharmaceutics. PMID 38331430 DOI: 10.1021/acs.molpharmaceut.3c01063 |
0.745 |
|
| 2024 |
Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson ME, Sanford R, Modi S, Agnew BJ, Lyashchenko SK, Lewis JS, ... ... Zeglis BM, et al. First-in-Human Evaluation of Site-Specifically Labeled Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 38272704 DOI: 10.2967/jnumed.123.266392 |
0.51 |
|
| 2023 |
Bauer D, Cornejo MA, Hoang TT, Lewis JS, Zeglis BM. Click Chemistry and Radiochemistry: An Update. Bioconjugate Chemistry. PMID 37737084 DOI: 10.1021/acs.bioconjchem.3c00286 |
0.4 |
|
| 2023 |
Delaney S, Rodriguez C, Sarrett SM, Dayts EJ, Zeglis BM, Keinänen O. Unraveling the in vivo fate of inhaled micro- and nanoplastics with PET imaging. The Science of the Total Environment. 904: 166320. PMID 37586535 DOI: 10.1016/j.scitotenv.2023.166320 |
0.732 |
|
| 2023 |
Delaney S, Sebastiano J, Zeglis BM, Keinänen OM. Molecular Imaging, Radiochemistry, and Environmental Pollutants. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 37442598 DOI: 10.2967/jnumed.122.265209 |
0.688 |
|
| 2023 |
Keinänen O, Sarrett SM, Delaney S, Rodriguez C, Dayts EJ, Capone E, Sauniere F, Ippoliti R, Sala G, Iacobelli S, Zeglis BM. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET. Molecular Pharmaceutics. PMID 37191353 DOI: 10.1021/acs.molpharmaceut.3c00241 |
0.76 |
|
| 2023 |
Bauer D, Sarrett SM, Lewis JS, Zeglis BM. Click chemistry: a transformative technology in nuclear medicine. Nature Protocols. PMID 37100960 DOI: 10.1038/s41596-023-00825-8 |
0.382 |
|
| 2022 |
Zeglis BM, Lewis JS. Click Here for Better Chemistry. The New England Journal of Medicine. PMID 36449446 DOI: 10.1056/NEJMcibr2213596 |
0.373 |
|
| 2022 |
MacPherson DS, Hwang D, Sarrett SM, Keinänen O, Rodriguez C, Rader C, Zeglis BM. Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate. Molecular Pharmaceutics. PMID 36377696 DOI: 10.1021/acs.molpharmaceut.2c00700 |
0.751 |
|
| 2022 |
Feng Y, Sarrett SM, Meshaw RL, Vaidyanathan G, Cornejo MA, Zeglis BM, Zalutsky MR. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent. Journal of Medicinal Chemistry. PMID 36368007 DOI: 10.1021/acs.jmedchem.2c01331 |
0.313 |
|
| 2022 |
Sarrett SM, Rodriguez C, Rymarczyk G, Hosny MM, Keinänen O, Delaney S, Thau S, Krantz BA, Zeglis BM. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates. Bioconjugate Chemistry. PMID 35946495 DOI: 10.1021/acs.bioconjchem.2c00354 |
0.758 |
|
| 2022 |
Rodriguez C, Delaney S, Sarrett SM, Keinänen OM, Zeglis BM. Antibody Engineering for Nuclear Imaging and Radioimmunotherapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 35863894 DOI: 10.2967/jnumed.122.263861 |
0.72 |
|
| 2022 |
Maitz CA, Delaney S, Cook BE, Genady AR, Hoerres R, Kuchuk M, Makris G, Valliant JF, Sadeghi S, Lewis JS, Hennkens HM, Bryan JN, Zeglis BM. Pretargeted PET of Osteodestructive Lesions in Dogs. Molecular Pharmaceutics. PMID 35635337 DOI: 10.1021/acs.molpharmaceut.2c00220 |
0.444 |
|
| 2022 |
Kunihiro AG, Sarrett SM, Lastwika KJ, Solan JL, Pisarenko T, Keinänen O, Rodriguez C, Taverne LR, Fitzpatrick AL, Li CI, Houghton AM, Zeglis BM, Lampe PD. CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 35483965 DOI: 10.2967/jnumed.121.263511 |
0.725 |
|
| 2021 |
Sharma SK, Mack KN, Piersigilli A, Pourat J, Edwards KJ, Keinänen O, Jiao MS, Zhao H, White B, Brooks CL, de Stanchina E, Madiyalakan R, Hollingsworth MA, Radhakrishnan P, Lewis JS, ... Zeglis BM, et al. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34907079 DOI: 10.1158/1078-0432.CCR-21-1798 |
0.768 |
|
| 2021 |
Sarrett SM, Keinänen O, Dayts EJ, Dewaele-Le Roi G, Rodriguez C, Carnazza KE, Zeglis BM. Inverse electron demand Diels-Alder click chemistry for pretargeted PET imaging and radioimmunotherapy. Nature Protocols. PMID 34127865 DOI: 10.1038/s41596-021-00540-2 |
0.767 |
|
| 2021 |
Keinänen O, Dayts EJ, Rodriguez C, Sarrett SM, Brennan JM, Sarparanta M, Zeglis BM. Harnessing PET to track micro- and nanoplastics in vivo. Scientific Reports. 11: 11463. PMID 34075133 DOI: 10.1038/s41598-021-90929-6 |
0.77 |
|
| 2021 |
Sharma SK, Adumeau P, Keinänen O, Sisodiya V, Sarvaiya H, Tchelepi R, Korsen JA, Pourat J, Edwards KJ, Ragupathi A, Hamdy O, Saunders LR, Rudin CM, Poirier JT, Lewis JS, ... Zeglis BM, et al. Synthesis and Comparative Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjugate Chemistry. PMID 33835770 DOI: 10.1021/acs.bioconjchem.1c00121 |
0.787 |
|
| 2021 |
Imlimthan S, Khng YC, Keinänen O, Zhang W, Airaksinen AJ, Kostiainen MA, Zeglis BM, Santos HA, Sarparanta M. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. Small (Weinheim An Der Bergstrasse, Germany). e2007705. PMID 33738957 DOI: 10.1002/smll.202007705 |
0.744 |
|
| 2020 |
Xiao G, Annor GK, Fung K, Keinänen O, Zeglis BM, Bargonetti J. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Molecular Pharmaceutics. PMID 33289569 DOI: 10.1021/acs.molpharmaceut.0c00978 |
0.736 |
|
| 2020 |
Keinänen O, Fung K, Brennan JM, Zia N, Harris M, van Dam E, Biggin C, Hedt A, Stoner J, Donnelly PS, Lewis JS, Zeglis BM. Harnessing Cu/Cu for a theranostic approach to pretargeted radioimmunotherapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 33106429 DOI: 10.1073/pnas.2009960117 |
0.737 |
|
| 2020 |
Fung K, Sharma SK, Keinänen O, Long Roche K, Lewis JS, Zeglis BM. A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High Grade Serous Ovarian Cancer. Molecular Pharmaceutics. PMID 32644804 DOI: 10.1021/Acs.Molpharmaceut.0C00437 |
0.774 |
|
| 2020 |
Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. Radiology. 192828. PMID 32515679 DOI: 10.1148/Radiol.2020192828 |
0.511 |
|
| 2020 |
Fung K, Vivier D, Keinänen O, Sarbisheh EK, Price EW, Zeglis BM. Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe. Molecules (Basel, Switzerland). 25. PMID 32429033 DOI: 10.3390/Molecules25102315 |
0.766 |
|
| 2020 |
White JM, Keinänen OM, Cook BE, Zeglis BM, Gibson HM, Viola NT. Removal of Fc Glycans from [Zr]Zr-DFO-anti-CD8 prevents peripheral depletion of CD8 T cells. Molecular Pharmaceutics. PMID 32330387 DOI: 10.1021/Acs.Molpharmaceut.0C00270 |
0.752 |
|
| 2020 |
Jannetti SA, Zeglis BM, Zalutsky MR, Reiner T. Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy. Frontiers in Pharmacology. 11: 170. PMID 32194409 DOI: 10.3389/Fphar.2020.00170 |
0.355 |
|
| 2020 |
Imberti C, Adumeau P, Blower JE, Al Salemee F, Baguña Torres J, Lewis JS, Zeglis BM, Terry SYA, Blower PJ. Manipulating the In Vivo Behaviour of Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance. International Journal of Molecular Sciences. 21. PMID 32098299 DOI: 10.3390/Ijms21041496 |
0.505 |
|
| 2020 |
Pirovano G, Jannetti SA, Carter LM, Sadique A, Kossatz S, Guru N, Demétrio De Souza França P, Maeda M, Zeglis BM, Lewis JS, Humm JL, Reiner T. Targeted brain tumor radiotherapy using an Auger emitter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32066626 DOI: 10.1158/1078-0432.Ccr-19-2440 |
0.492 |
|
| 2020 |
Vivier D, Fung K, Rodriguez C, Adumeau P, Ulaner GA, Lewis JS, Sharma SK, Zeglis BM. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and Performance of Zr-DFO-Pertuzumab. Theranostics. 10: 1746-1757. PMID 32042334 DOI: 10.7150/Thno.39089 |
0.56 |
|
| 2019 |
Rondon A, Schmitt S, Briat A, Ty N, Maigne L, Quintana M, Membreno R, Zeglis BM, Navarro-Teulon I, Pouget JP, Chezal JM, Miot-Noirault E, Moreau E, Degoul F. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept. Theranostics. 9: 6706-6718. PMID 31588245 DOI: 10.7150/Thno.35461 |
0.398 |
|
| 2019 |
MacPherson DS, Fung K, Cook BE, Francesconi LC, Zeglis BM. A brief overview of metal complexes as nuclear imaging agents. Dalton Transactions (Cambridge, England : 2003). PMID 31556418 DOI: 10.1039/C9Dt03039E |
0.349 |
|
| 2019 |
Keinänen O, Brennan J, Membreno R, Fung K, Gangangari K, Dayts E, Williams CJ, Zeglis BM. Dual Radionuclide Theranostic Pretargeting. Molecular Pharmaceutics. PMID 31483993 DOI: 10.1021/Acs.Molpharmaceut.9B00746 |
0.747 |
|
| 2019 |
Membreno R, Keinänen OM, Cook BE, Tully KM, Fung KC, Lewis JS, Zeglis BM. Towards the Optimization of Click-Mediated Pretargeted Radioimmunotherapy. Molecular Pharmaceutics. PMID 30912951 DOI: 10.1021/Acs.Molpharmaceut.9B00062 |
0.776 |
|
| 2019 |
Davydova M, Dewaele Le Roi G, Adumeau P, Zeglis BM. Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates. Journal of Visualized Experiments : Jove. PMID 30907883 DOI: 10.3791/59063 |
0.428 |
|
| 2019 |
Membreno R, Cook BE, Zeglis BM. Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction. Journal of Visualized Experiments : Jove. PMID 30774125 DOI: 10.3791/59041 |
0.47 |
|
| 2019 |
Vivier D, Sharma SK, Adumeau P, Rodriguez C, Fung K, Zeglis B. The Impact of FcγRI Binding on ImmunoPET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30733320 DOI: 10.2967/Jnumed.118.223636 |
0.469 |
|
| 2019 |
Walsh J, Francesconi L, Sanders V, Iskhakov D, Zeglis B, Lewis J. Improving excretory pathways of technetium-99m SPECT imaging agents based on bioorthogonal Diels-Alder click chemistry Nuclear Medicine and Biology. DOI: 10.1016/S0969-8051(19)30366-X |
0.484 |
|
| 2019 |
Fung K, Vivier D, Price E, Zeglis B. Development of a MUC1-targeting PET probe for ovarian cancer Nuclear Medicine and Biology. DOI: 10.1016/S0969-8051(19)30346-4 |
0.347 |
|
| 2019 |
Membreno R, Cook B, Tully K, Lewis J, Zeglis B. The optimization of click-mediated pretargeted radioimmunotherapy Nuclear Medicine and Biology. DOI: 10.1016/S0969-8051(19)30237-9 |
0.414 |
|
| 2019 |
Cook B, Membreno R, Zeglis B. Bifunctional dendrimer scaffold leads to increased tumor uptake Nuclear Medicine and Biology. DOI: 10.1016/S0969-8051(19)30232-X |
0.318 |
|
| 2019 |
Poty S, Knight J, Mandleywala K, Membreno R, Abdel-Atti D, Scholz W, Zeglis B, Cornelissen B, Lewis J. Pretargeted 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma: evaluating DNA-damage with 89Zr-PET Nuclear Medicine and Biology. DOI: 10.1016/S0969-8051(19)30231-8 |
0.46 |
|
| 2018 |
Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. Leveraging bioorthogonal click chemistry to improve 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30352909 DOI: 10.1158/1078-0432.Ccr-18-1650 |
0.518 |
|
| 2018 |
Cook BE, Membreno R, Zeglis BM. A Dendrimer Scaffold for the Amplification of In Vivo Pretargeting Ligations. Bioconjugate Chemistry. PMID 29969558 DOI: 10.1021/Acs.Bioconjchem.8B00385 |
0.461 |
|
| 2018 |
Jannetti SA, Carlucci G, Carney B, Kossatz S, Shenker L, Carter LM, Salinas B, Brand C, Sadique A, Donabedian PL, Cunanan KM, Gönen M, Ponomarev V, Zeglis BM, Souweidane MM, et al. PARP1-Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29572254 DOI: 10.2967/Jnumed.117.205054 |
0.542 |
|
| 2018 |
Adumeau P, Davydova M, Zeglis BM. Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability. Bioconjugate Chemistry. 29: 1364-1372. PMID 29509393 DOI: 10.1021/Acs.Bioconjchem.8B00081 |
0.392 |
|
| 2018 |
Membreno R, Cook BE, Fung K, Lewis JS, Zeglis BM. Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. Molecular Pharmaceutics. PMID 29502416 DOI: 10.1021/Acs.Molpharmaceut.8B00093 |
0.578 |
|
| 2018 |
Poty S, Membreno R, Glaser JM, Ragupathi A, Scholz WW, Zeglis BM, Lewis JS. The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of 225Ac-labelled radioimmunoconjugates. Chemical Communications (Cambridge, England). PMID 29388990 DOI: 10.1039/C7Cc09129J |
0.458 |
|
| 2018 |
Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, Dilling TR, Abdel-Atti D, Zeglis BM, Poirier JT, Lewis JS. Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Research. PMID 29363548 DOI: 10.1158/0008-5472.Can-17-1958 |
0.552 |
|
| 2018 |
Adumeau P, Vivier D, Sharma SK, Wang J, Zhang T, Chen A, Agnew BJ, Zeglis BM. A Site-Specifically Modified Imaging-Enabled Antibody-Drug Conjugate for Therapy and ImmunoPET. Molecular Pharmaceutics. PMID 29356543 DOI: 10.1021/Acs.Molpharmaceut.7B00802 |
0.475 |
|
| 2017 |
Keinänen O, Fung K, Pourat J, Jallinoja V, Vivier D, Pillarsetty NK, Airaksinen AJ, Lewis JS, Zeglis BM, Sarparanta M. Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models. Ejnmmi Research. 7: 95. PMID 29198065 DOI: 10.1186/S13550-017-0344-6 |
0.763 |
|
| 2017 |
Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA. First-in-human HER2-targeted imaging using (89)Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29146695 DOI: 10.2967/Jnumed.117.202010 |
0.48 |
|
| 2017 |
Meyer JP, Kozlowski P, Jackson J, Cunanan KM, Adumeau P, Dilling TR, Zeglis BM, Lewis JS. Exploring Structural Parameters for Pretargeting Radioligand Optimization. Journal of Medicinal Chemistry. PMID 28857566 DOI: 10.1021/Acs.Jmedchem.7B01108 |
0.545 |
|
| 2017 |
Altai M, Membreno R, Cook B, Tolmachev V, Zeglis B. Pretargeted Imaging and Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28687600 DOI: 10.2967/Jnumed.117.189944 |
0.436 |
|
| 2017 |
Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, ... ... Zeglis BM, et al. Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. Cancer Research. PMID 28487384 DOI: 10.1158/0008-5472.Can-17-0299 |
0.59 |
|
| 2017 |
Büchel GE, Carney B, Tang J, Zeglis BM, Eppinger J, Reiner T. A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting. Journal of Visualized Experiments : Jove. PMID 28362395 DOI: 10.3791/54694 |
0.329 |
|
| 2017 |
Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, Zanzonico PB, Lewis JS, Zeglis BM. Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. Molecular Cancer Therapeutics. 16: 124-133. PMID 28062708 DOI: 10.1158/1535-7163.Mct-16-0503 |
0.606 |
|
| 2016 |
Adumeau P, Carnazza KE, Brand C, Carlin SD, Reiner T, Agnew BJ, Lewis JS, Zeglis BM. A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. Theranostics. 6: 2267-2277. PMID 27924162 DOI: 10.7150/Thno.16744 |
0.606 |
|
| 2016 |
Meyer JP, Adumeau P, Lewis JS, Zeglis BM. Click Chemistry and Radiochemistry: The First Ten Years. Bioconjugate Chemistry. PMID 27787983 DOI: 10.1021/Acs.Bioconjchem.6B00561 |
0.513 |
|
| 2016 |
Büchel GE, Carney B, Shaffer TM, Tang J, Austin C, Arora M, Zeglis BM, Grimm J, Eppinger J, Reiner T. Near-Infrared Intraoperative Chemiluminescence Imaging. Chemmedchem. PMID 27471800 DOI: 10.1002/Cmdc.201600301 |
0.325 |
|
| 2016 |
Price EW, Edwards KJ, Carnazza KE, Carlin SD, Zeglis BM, Adam MJ, Orvig C, Lewis JS. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y. Nuclear Medicine and Biology. 43: 566-576. PMID 27419360 DOI: 10.1016/J.Nucmedbio.2016.06.004 |
0.466 |
|
| 2016 |
Cook BE, Adumeau P, Membreno R, Carnazza KE, Brand C, Reiner T, Agnew BJ, Lewis JS, Zeglis BM. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. Bioconjugate Chemistry. PMID 27356886 DOI: 10.1021/Acs.Bioconjchem.6B00235 |
0.623 |
|
| 2016 |
Sharma SK, Nemieboka B, Sala E, Lewis JS, Zeglis BM. Molecular Imaging of Ovarian Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27127223 DOI: 10.2967/Jnumed.115.172023 |
0.53 |
|
| 2016 |
Sharma SK, Sevak KK, Monette S, Carlin SD, Knight JC, Wuest FR, Sala E, Zeglis BM, Lewis JS. Preclinical 89Zr-immunoPET of High Grade Serous Ovarian Cancer and Lymph Node Metastasis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26837339 DOI: 10.2967/Jnumed.115.167072 |
0.496 |
|
| 2016 |
Adumeau P, Sharma SK, Brent C, Zeglis BM. Site-Specifically Labeled Immunoconjugates for Molecular Imaging-Part 2: Peptide Tags and Unnatural Amino Acids. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 26754791 DOI: 10.1007/S11307-015-0920-Y |
0.408 |
|
| 2016 |
Adumeau P, Sharma SK, Brent C, Zeglis BM. Site-Specifically Labeled Immunoconjugates for Molecular Imaging-Part 1: Cysteine Residues and Glycans. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 18: 1-17. PMID 26754790 DOI: 10.1007/S11307-015-0919-4 |
0.424 |
|
| 2016 |
Houghton J, Membreno R, Abdel-Atti D, Scholz WW, Zeglis BM, Lewis JS. Abstract 3051: Improving the efficacy of pretargeted radioimmunotherapy in preclinical murine models by utilizing bioorthogonal click chemistry Cancer Research. 76: 3051-3051. DOI: 10.1158/1538-7445.Am2016-3051 |
0.587 |
|
| 2015 |
Houghton JL, Zeglis BM, Abdel-Atti D, Aggeler R, Sawada R, Agnew BJ, Scholz WW, Lewis JS. Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 26668398 DOI: 10.1073/Pnas.1506542112 |
0.589 |
|
| 2015 |
Meyer JP, Houghton JL, Kozlowski P, Abdel-Atti D, Reiner T, Pillarsetty NV, Scholz WW, Zeglis BM, Lewis JS. (18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. Bioconjugate Chemistry. PMID 26479967 DOI: 10.1021/Acs.Bioconjchem.5B00504 |
0.551 |
|
| 2015 |
Houghton JL, Zeglis BM, Abdel-Atti D, Sawada R, Scholz WW, Lewis JS. Pretargeted immunoPET of pancreatic cancer: overcoming circulating antigen and antibody internalization to reduce radiation doses. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26471693 DOI: 10.2967/Jnumed.115.163824 |
0.566 |
|
| 2015 |
Zeglis BM, Brand C, Abdel-Atti D, Carnazza KE, Cook BE, Carlin S, Reiner T, Lewis JS. Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. Molecular Pharmaceutics. PMID 26287993 DOI: 10.1021/Acs.Molpharmaceut.5B00294 |
0.614 |
|
| 2015 |
Reiner T, Lewis JS, Zeglis BM. Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging. Journal of Visualized Experiments : Jove. e52335. PMID 25742199 DOI: 10.3791/52335 |
0.624 |
|
| 2015 |
Zeglis BM, Lewis JS. The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. Journal of Visualized Experiments : Jove. PMID 25741890 DOI: 10.3791/52521 |
0.593 |
|
| 2014 |
Zeglis BM, Davis CB, Abdel-Atti D, Carlin SD, Chen A, Aggeler R, Agnew BJ, Lewis JS. Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. Bioconjugate Chemistry. 25: 2123-8. PMID 25418333 DOI: 10.1021/Bc500499H |
0.599 |
|
| 2014 |
Daumar P, Zeglis BM, Ramos N, Divilov V, Sevak KK, Pillarsetty N, Lewis JS. Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. European Journal of Medicinal Chemistry. 86: 769-81. PMID 25240701 DOI: 10.1016/J.Ejmech.2014.09.019 |
0.522 |
|
| 2014 |
Price EW, Zeglis BM, Cawthray JF, Lewis JS, Adam MJ, Orvig C. What a difference a carbon makes: H₄octapa vs H₄C3octapa, ligands for In-111 and Lu-177 radiochemistry. Inorganic Chemistry. 53: 10412-31. PMID 25192223 DOI: 10.1021/Ic501466Z |
0.468 |
|
| 2014 |
Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, Francesconi LC. Alternative chelator for â¸â¹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). Journal of Medicinal Chemistry. 57: 4849-60. PMID 24814511 DOI: 10.1021/Jm500389B |
0.568 |
|
| 2014 |
Zeglis BM, Emmetiere F, Pillarsetty N, Weissleder R, Lewis JS, Reiner T. Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. Chemistryopen. 3: 48-53. PMID 24808990 DOI: 10.1002/Open.201402000 |
0.458 |
|
| 2014 |
Reiner T, Zeglis BM. The inverse electron demand Diels-Alder click reaction in radiochemistry. Journal of Labelled Compounds & Radiopharmaceuticals. 57: 285-90. PMID 24347429 DOI: 10.1002/Jlcr.3149 |
0.369 |
|
| 2014 |
Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorganic Chemistry. 53: 1880-99. PMID 24313747 DOI: 10.1021/Ic401607Z |
0.51 |
|
| 2014 |
Price EW, Zeglis BM, Lewis JS, Adam MJ, Orvig C. H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. Dalton Transactions (Cambridge, England : 2003). 43: 119-31. PMID 24104523 DOI: 10.1039/C3Dt51940F |
0.557 |
|
| 2014 |
Sharma SK, Zeglis B, Sevak K, Lewis J, Wuest F. 89Zr immuno-PET of epithelial ovarian cancer Nuclear Medicine and Biology. 41: 638-639. DOI: 10.1016/J.Nucmedbio.2014.05.114 |
0.489 |
|
| 2014 |
Zeglis BM, Davis CB, Aggeler R, Agnew BJ, Lewis JS. The site-specific radiometallation of antibodies on the heavy chain glycans Nuclear Medicine and Biology. 41: 636. DOI: 10.1016/J.Nucmedbio.2014.05.110 |
0.498 |
|
| 2014 |
Deri MA, Ponnala S, Zeglis BM, Pohl G, Dannenberg JJ, Lewis JS, Francesconi LC. 3,4,3-(LI-1,2-HOPO): An alternative chelator for 89Zr radiopharmaceuticals Nuclear Medicine and Biology. 41: 629. DOI: 10.1016/J.Nucmedbio.2014.05.103 |
0.44 |
|
| 2014 |
Price EW, Zeglis BM, Cawthray JF, Lewis JS, Adam MJ, Orvig C. H4octapa vs H4C3octapa: The difference of a single carbon atom Nuclear Medicine and Biology. 41: 635. DOI: 10.1016/J.Nucmedbio.2014.05.032 |
0.399 |
|
| 2014 |
Zeng D, Zeglis BM, Lewis JS, Anderson CJ. ChemInform Abstract: The Growing Impact of Bioorthogonal Click Chemistry on the Development of Radiopharmaceuticals Cheminform. 45: no-no. DOI: 10.1002/CHIN.201439276 |
0.365 |
|
| 2013 |
Price EW, Zeglis BM, Cawthray JF, Ramogida CF, Ramos N, Lewis JS, Adam MJ, Orvig C. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy. Journal of the American Chemical Society. 135: 12707-21. PMID 23901833 DOI: 10.1021/Ja4049493 |
0.61 |
|
| 2013 |
Zeglis BM, Sevak KK, Reiner T, Mohindra P, Carlin SD, Zanzonico P, Weissleder R, Lewis JS. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 1389-96. PMID 23708196 DOI: 10.2967/Jnumed.112.115840 |
0.592 |
|
| 2013 |
Zeglis BM, Davis CB, Aggeler R, Kang HC, Chen A, Agnew BJ, Lewis JS. Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjugate Chemistry. 24: 1057-67. PMID 23688208 DOI: 10.1021/Bc400122C |
0.57 |
|
| 2013 |
Zeng D, Zeglis BM, Lewis JS, Anderson CJ. The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 829-32. PMID 23616581 DOI: 10.2967/Jnumed.112.115550 |
0.52 |
|
| 2013 |
Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. Nuclear Medicine and Biology. 40: 3-14. PMID 22998840 DOI: 10.1016/J.Nucmedbio.2012.08.004 |
0.56 |
|
| 2013 |
Zeglis BM, Holland JP, Lebedev AY, Cantorias MV, Lewis JS. Radiopharmaceuticals for imaging in oncology with special emphasis on positron-emitting agents Nuclear Oncology: Pathophysiology and Clinical Applications. 35-78. DOI: 10.1007/978-0-387-48894-3_3 |
0.695 |
|
| 2012 |
Bailey GA, Price EW, Zeglis BM, Ferreira CL, Boros E, Lacasse MJ, Patrick BO, Lewis JS, Adam MJ, Orvig C. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu. Inorganic Chemistry. 51: 12575-89. PMID 23106422 DOI: 10.1021/Ic302225Z |
0.481 |
|
| 2011 |
Zeglis BM, Mohindra P, Weissmann GI, Divilov V, Hilderbrand SA, Weissleder R, Lewis JS. Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjugate Chemistry. 22: 2048-59. PMID 21877749 DOI: 10.1021/Bc200288D |
0.573 |
|
| 2011 |
Zeglis BM, Pillarsetty N, Divilov V, Blasberg RA, Lewis JS. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nuclear Medicine and Biology. 38: 683-96. PMID 21718944 DOI: 10.1016/J.Nucmedbio.2010.12.008 |
0.484 |
|
| 2011 |
Zeglis BM, Lewis JS. A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. Dalton Transactions (Cambridge, England : 2003). 40: 6168-95. PMID 21442098 DOI: 10.1039/C0Dt01595D |
0.575 |
|
| 2011 |
Zeglis BM, Divilov V, Lewis JS. Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes. Journal of Medicinal Chemistry. 54: 2391-8. PMID 21391686 DOI: 10.1021/Jm101532U |
0.463 |
|
| 2011 |
Arrowsmith RL, Zeglis BM, Viola-Villegas N, Divilov, Jones M, Waghorn PA, Phillips FL, Mindt TL, Eggleston IM, Botchway SW, Dilworth JR, Aigbirhio FI, Lewis JS, Pascu SI. Fluorescent copper(II), gallium(III) and indium(III) bis(thiosemicarbazonates):Radiolabeling, cellular confocal fluorescence and PET imaging studies Journal of Labelled Compounds and Radiopharmaceuticals. 54. DOI: 10.1002/Jlcr.1925 |
0.488 |
|
| 2009 |
Zeglis BM, Pierre VC, Kaiser JT, Barton JK. A bulky rhodium complex bound to an adenosine-adenosine DNA mismatch: general architecture of the metalloinsertion binding mode. Biochemistry. 48: 4247-53. PMID 19374348 DOI: 10.1021/Bi900194E |
0.679 |
|
| 2009 |
Zeglis BM, Boland JA, Barton JK. Recognition of abasic sites and single base bulges in DNA by a metalloinsertor. Biochemistry. 48: 839-49. PMID 19146409 DOI: 10.1021/Bi801885W |
0.466 |
|
| 2008 |
Zeglis BM, Barton JK. Binding of Ru(bpy)2(eilatin)2+ to matched and mismatched DNA. Inorganic Chemistry. 47: 6452-7. PMID 18576614 DOI: 10.1021/Ic8006537 |
0.454 |
|
| 2008 |
Zeglis BM, Boland JA, Barton JK. Targeting abasic sites and single base bulges in DNA with metalloinsertors. Journal of the American Chemical Society. 130: 7530-1. PMID 18491905 DOI: 10.1021/Ja801479Y |
0.462 |
|
| 2007 |
Zeglis BM, Pierre VC, Barton JK. Metallo-intercalators and metallo-insertors. Chemical Communications (Cambridge, England). 4565-79. PMID 17989802 DOI: 10.1039/B710949K |
0.694 |
|
| 2007 |
Zeglis BM, Barton JK. DNA base mismatch detection with bulky rhodium intercalators: synthesis and applications. Nature Protocols. 2: 357-71. PMID 17406597 DOI: 10.1038/Nprot.2007.22 |
0.475 |
|
| 2006 |
Zeglis BM, Barton JK. A mismatch-selective bifunctional rhodium-Oregon Green conjugate: a fluorescent probe for mismatched DNA. Journal of the American Chemical Society. 128: 5654-5. PMID 16637630 DOI: 10.1021/Ja061409C |
0.467 |
|
| 2004 |
Chianese AR, Zeglis BM, Crabtree RH. Unexpected oxidative C-C cleavage in the metallation of 2-substituted imidazolium salts to give N-heterocyclic carbene complexes. Chemical Communications (Cambridge, England). 2176-7. PMID 15467859 DOI: 10.1039/B409672J |
0.311 |
|
| 2004 |
Chianese AR, Kovacevic A, Zeglis BM, Faller JW, Crabtree RH. Abnormal C5-bound N-heterocyclic carbenes: Extremely strong electron donor ligands and their iridium(I) and iridium(III) complexes Organometallics. 23: 2461-2468. DOI: 10.1021/Om049903H |
0.417 |
|
| Show low-probability matches. |